Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis

• Published in: Frontiers in immunology Vol. 12; p. 751407
• Main Authors: Li, Yan, Ma, Yiqi, Wu, Zijun, Zeng, Fanxin, Song, Bin, Zhang, Yanrong, Li, Jinxing, Lui, Su, Wu, Min
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.09.2021
• Subjects: Biomarkers, Tumor - genetics; Cohort Studies; colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Humans; immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; Immunology; Mutation; objective response rate; overall survival; Randomized Controlled Trials as Topic; Treatment Outcome; tumor mutation burden; overall survival; colorectal cancer; objective response rate; immune checkpoint inhibitors; tumor mutation burden
• DOI: 10.3389/fimmu.2021.751407
• ISSN: 1664-3224

For colorectal cancer patients, traditional biomarker deficient mismatch repair/microsatellite instability (dMMR/MSI) is an accurate predictor of immune checkpoint inhibitors (ICIs). Recent years, researchers considered tumor mutation burden (TMB) as another predictive biomarker which means the number of nonsynonymous mutations in cancer cells. Several studies have proven that TMB can evaluate the efficacy of ICI therapy in diverse types of cancer, especially in non-small cell lung cancer and melanoma. However, studies on the association between TMB and the response to ICI therapy in colorectal cancer alone are still lacking. In this study, we aim to verify the effect of TMB as a biomarker in predicting the efficacy of ICIs in colorectal cancer. We searched the PubMed and Ovid MEDLINE databases up to May 1, 2021 and screened studies for eligibility. Thirteen studies published from 2015 to 2021 with 5062 patients were included finally. We extracted and calculated hazard ratios (HRs) and odds ratios (ORs) of overall survival (OS) and objective response rates (ORRs) and their 95% confidence intervals (95% CIs). Pooled HR and OR were evaluated to compare OS and ORR between TMB-high and TMB-low groups in colorectal cancer patients. Meanwhile, we assessed heterogeneity with the statistic and p-values and performed publication bias assessments, sensitivity analyses, and subgroup analyses to search the cause of heterogeneity. The TMB-high patient group had a longer OS than the TMB-low patient group (HR = 0.68, 95% CI: 0.51, 0.92, p = 0.013) among colorectal cancer patients receiving ICIs. In addition, the TMB-high patient group was superior in terms of ORR (OR = 19.25, 95% CI: 10.06, 36.82, p < 0.001) compared to the TMB-low patient group. In conclusion, this meta-analysis revealed that TMB can be used as a potential predictive biomarker of colorectal cancer patients receiving ICI therapy. Nevertheless, this finding is not stable enough. Therefore, many more randomized controlled trials are needed to prove that TMB is reliable enough to be used clinically to predict the efficacy of immunotherapy in colorectal cancer. And the most relevant biomarker remains to be determined when TMB high overlaps with other biomarkers like MSI and TILs.